Important advances in oncology (IAO)

Important Advances in Oncology is a specialized oncology serial publication that compiles authoritative review articles and research chapters focusing on major developments in cancer science and clinical oncology. Published primarily by Lippincott (now part of Wolters Kluwer), it has served as a reference source for oncologists, medical researchers, and healthcare professionals interested in advances in cancer diagnosis, treatment, and biological understanding of malignancies. The publication is not a conventional monthly journal; instead, it is often issued in volume-based or monographic formats, where each volume contains in-depth scholarly reviews on selected oncology topics. These include cancer epidemiology, tumor immunology, chemotherapy innovations, molecular oncology, carcinogenesis, radiation therapy, gene therapy approaches, and emerging targeted therapies. Articles published in Important Advances in Oncology are typically comprehensive reviews written by experts, summarizing progress in specific subfields of oncology. This makes it particularly useful for clinicians and researchers who need consolidated updates on evolving cancer research rather than rapid short communications. Historically, the series has included influential contributions on immunotoxins, oncogenes, colony-stimulating factors, and experimental cancer therapies, reflecting major milestones in oncology research during the late 20th century. The publication has contributed to shaping clinical understanding and research direction in cancer medicine by providing high-level syntheses of ongoing scientific progress.

Important advances in oncology (IAO) is :-

• International, Peer-Reviewed, Open Access, Refereed, Oncology, Cancer Biology, Clinical Oncology, Medical Oncology, Chemotherapy Research, Tumor Biology, Carcinogenesis, Cancer Therapeutics, Hematologic Malignancies, cancer epidemiology, tumor immunology, chemotherapy innovations, molecular oncology, carcinogenesis, radiation therapy, gene therapy approaches, emerging targeted therapies , Online , Irregular Journal

• UGC Approved, ISSN Approved: P-ISSN E-ISSN: 0883-5896, Established: 1985,
• Does Not Provide Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE